All In Biotech

Drug Trial Radar · NCT04130997

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,100

Planned (sponsor's estimate)

Start

Nov 18, 2019

Primary completion

May 31, 2032

Study completion May 31, 2032

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).

Conditions

  • Relapsing Multiple Sclerosis (RMS)

Interventions

  • UblituximabBiological

    Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Up to Week 336

Locations

86 sites in 8 countries. Site status is shown where the registry gives one.

  • TG Therapeutics Investigational Trial Site

    Pasadena, California

  • TG Therapeutics Investigational Trial Site

    Denver, Colorado

  • TG Therapeutics Investigational Trial Site

    Miami, Florida

  • TG Therapeutics Investigational Trial Site

    Tampa, Florida

  • TG Therapeutics Investigational Trial Site

    Northbrook, Illinois

  • TG Therapeutics Investigational Trial Site

    Kansas City, Kansas

  • TG Therapeutics Investigational Trial Site

    Detroit, Michigan

  • TG Therapeutics Investigational Trial Site

    Las Vegas, Nevada

  • TG Therapeutics Investigational Trial Site

    Teaneck, New Jersey

  • TG Therapeutics Investigational Trial Site

    Albuquerque, New Mexico

  • TG Therapeutics Investigational Trial Site

    Amherst, New York

  • TG Therapeutics Investigational Trial Site

    Columbus, Ohio

  • TG Therapeutics Investigational Trial Site

    Westerville, Ohio

  • TG Therapeutics Investigational Trial Site

    Knoxville, Tennessee

  • TG Therapeutics Investigational Trial Site

    Dallas, Texas

  • TG Therapeutics Investigational Trial Site

    Frisco, Texas

  • TG Therapeutics Investigational Trial Site

    Round Rock, Texas

  • TG Therapeutics Investigational Trial Site

    San Antonio, Texas

  • TG Therapeutics Investigational Trial Site

    Seattle, Washington

  • TG Therapeutics Investigational Trial Site

    Grodno, Belarus

  • TG Therapeutics Investigational Trial Site

    Grodno, Belarus

  • TG Therapeutics Investigational Trial Site

    Minsk, Belarus

  • TG Therapeutics Investigational Trial Site

    Minsk, Belarus

  • TG Therapeutics Investigational Trial Site

    Minsk, Belarus

  • TG Therapeutics Investigational Trial Site

    Osijek, Croatia

  • TG Therapeutics Investigational Trial Site

    Varaždin, Croatia

  • TG Investigational Trial Site

    Zagreb, Croatia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Tbilisi, Georgia

  • TG Therapeutics Investigational Trial Site

    Katowice, Poland

  • TG Therapeutics Investigational Trial Site

    Katowice, Poland

  • TG Therapeutics Investigational Trial Site

    Katowice, Poland

  • TG Therapeutics Investigational Trial Site

    Krakow, Poland

  • TG Therapeutics Investigational Trial Site

    Lodz, Poland

  • TG Therapeutics Investigational Trial Site

    Olsztyn, Poland

  • TG Therapeutics Investigational Trial Site

    Poznan, Poland

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.